SULFADIAZINE
LOE ApproachingNDAORALTABLET
Approved
Aug 1941
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
SULFADIAZINE by Eli Lilly and Company is clinical pharmacology silver sulfadiazine has broad antimicrobial activity. First approved in 1941.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sulfadiazine is a sulfonamide antibiotic oral tablet approved in 1941 for bacterial infections. It works by inhibiting bacterial folate synthesis, making it a foundational antimicrobial agent. The drug treats various bacterial infections and has been a long-standing therapeutic option in infectious disease.
$0.78MPart D
LOE ApproachingMinimal linked job activity (0 positions) reflects mature, declining product with limited commercial expansion opportunities and likely reduced team headcount.
Mechanism of Action
CLINICAL PHARMACOLOGY Silver sulfadiazine has broad antimicrobial activity. It is bactericidal for many gram-negative and gram-positive bacteria as well as being effective against yeast. Results from in vitro testing are listed below. Sufficient data have been obtained to demonstrate that silver…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on SULFADIAZINE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.